Abstract

BAYON, Claudia; BARRIGA, Mercedes Araceli  and  LITWAK, León. Incretins, Incretinmimetics, Inhibitors. Rev. argent. endocrinol. metab. [online]. 2010, vol.47, n.1, pp.36-51. ISSN 1851-3034.

Two main patophysiological mechanisms are currently involved in Type 2 Diabetes (T2DM), insulin resistance and impairment of beta cell function. However in the last years a new mechanism was reported: a significant decrease in incretins production and or action. Incretins are gut hormones whose main action is stimulating insulin secretion in response to nutrients. The more known incretins are glucagon like peptide-1 (GLP-1) and Gastric insulinothropic peptide (GIP). GLP-1 and GIP not only increase insulin secretion, nor decrease glucagon secretion, slow gastric emptying and reduce apetite generating weight lose. Both incretins are rapidly clived by the enzyme dipeptidil peptidase 4 (DPP4). In order to emulate incretins action, several drugs where developed: agonists of GLP-1 receptors, GLP-1 mimetics, and inhibitors of the DPP4. All of them seems to became a very promise tool for the treatment of T2DM.

Keywords : Diabetes 2; Incretin; GLP-1; Exenatide; DPP-4.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )